GlassScriptPhysician profile
Kenneth R Lefkowitz
NPI 1073511580
$966.74
in general payments reported to CMS, 2019-2025
12 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $12.54 · 2022: $357 · 2023: $83.36 · 2024: $129 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $171.11 | 2022-2023 | Senza |
| Smith+Nephew, INC. | $162.79 | 2023-2025 | Oasis Micro, Grafix Pl, Stravix Pl |
| Organogenesis INC. | $122.35 | 2022 | |
| Biopro, INC. | $119.63 | 2019 | |
| Treace Medical Concepts, INC. | $112.33 | 2024 | |
| Alexion Pharmaceuticals, INC. | $103.74 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.46 | 2022 | |
| Medtronic, INC. | $46.37 | 2022 | |
| Averitas Pharma INC. | $28.48 | 2023-2025 | Qutenza |
| Stryker Corporation | $20.96 | 2023 | Phalinx |
| Paratek Pharmaceuticals, INC. | $16.98 | 2024 | Nuzyra |
| Zyla Life Sciences, INC. | $12.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Lefkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.